Holen Sie sich die Stockscreener-App
8.84
0.80%
0.07
Handel nachbörslich:
8.84
Schlusskurs vom Vortag:
$8.77
Offen:
$8.75
24-Stunden-Volumen:
37,514
Relative Volume:
0.56
Marktkapitalisierung:
$752.23M
Einnahmen:
$213.45M
Nettoeinkommen (Verlust:
$-72.46M
KGV:
-8.8969
EPS:
-0.9936
Netto-Cashflow:
$-47.28M
1W Leistung:
+0.00%
1M Leistung:
+17.87%
6M Leistung:
+29.24%
1J Leistung:
+22.78%
1-Tages-Spanne:
$8.75
$8.9818
1-Wochen-Bereich:
$8.0528
$9.11
52-Wochen-Spanne:
$3.62
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Vergleichen Sie VALN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
8.84 | 733.40M | 213.45M | -72.46M | -47.28M | -0.9936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-08-03 | Eingeleitet | H.C. Wainwright | Buy |
Valneva Se Adr Aktie (VALN) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out - ACCESS Newswire
Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ - MSN
Valneva selloff on FDA suspension overdone, says H.C. Wainwright - MSN
Valneva SE ADR: Rising -26.86% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Valneva price target lowered to $14 from $18 at Jefferies - MSN
Jefferies lowers Valneva stock price target to $14 on FDA suspension - Investing.com
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine By Investing.com - Investing.com South Africa
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine - Investing.com
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. - GlobeNewswire Inc.
Valneva (NASDAQ:VALN) Shares Gap Up – Still a Buy? - Defense World
HC Wainwright Estimates Valneva’s Q3 Earnings (NASDAQ:VALN) - Defense World
Valneva (NASDAQ:VALN) Coverage Initiated by Analysts at HC Wainwright - Defense World
Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 91.2% - Defense World
Valneva (NASDAQ:VALN) Trading Up 14.3% After Better-Than-Expected Earnings - Defense World
Valneva (NASDAQ:VALN) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Valneva SE earnings beat by $0.22, revenue topped estimates - Investing.com
Valneva (NASDAQ:VALN) Trading Down 6.7% – Here’s What Happened - Defense World
Valneva (NASDAQ:VALN) Sets New 1-Year High – Still a Buy? - Defense World
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock? - Yahoo Finance
[Valneva SE] Declaration of shares and voting rights - GlobeNewswire Inc.
Valneva SE earnings missed by $0.01, revenue topped estimates - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - Louisiana First News
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
Valneva SE Company Investigated by the Portnoy Law Firm - GlobeNewswire
Valneva shares leap on Brazilian approval of chikungunya vaccine By Investing.com - Investing.com India
Valneva shares leap on Brazilian approval of chikungunya vaccine - Investing.com Australia
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
VALN Doses First Infant With Shigella Vaccine In Mid-Stage Study - Barchart.com
H.C. Wainwright maintains Buy on Valneva with $17 price target - Investing.com
Valneva SE ADR’s Banking’s 100-Day Moving Average at 5.61: Will the Stock Break Through? - investchronicle.com
The Schall Law Probes Valneva Over Vaccine Safety Concerns - Lawyer Monthly
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - Business Wire
Finanzdaten der Valneva Se Adr-Aktie (VALN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):